GET DAILY SIGNALSTelomir Pharmaceuticals (TELO) Stock Declines -17% Over the Past Month
Key Takeaways
- TELO shares declined roughly 17% over the last 30 days, falling from about $1.23 in late September to approximately $1.02 at the most recent close.
- The drop followed a sharp, short-lived spike in early October, when the stock touched an intraday high near $1.58 before reversing lower.
- A dilutive $5.6 million PIPE financing, ongoing capital-raising needs, and a pre-revenue, clinical-stage profile weighed on sentiment.
- The company has transitioned toward clinical development after the FDA cleared its IND for Telomir-Zn in triple-negative breast cancer.
- Micro-cap volatility, low trading liquidity, and a going-concern disclosure remain key risk factors for the stock.
- Get more detail on Telomir's Price Targets, Earnings, and Forecast on additional pages.
- Explore Trending AI Robots to see AI-driven trading strategies in action.
Company Background and Current Focus
Telomir Pharmaceuticals, Inc. is a Miami, Florida-based clinical-stage biotechnology company developing small-molecule therapeutics that target epigenetic and metabolic drivers of cancer, aging, and degenerative disease. Its lead investigational candidate, Telomir-1 (Telomir-Zn), is an oral small molecule designed to modulate intracellular metal homeostasis—particularly iron and copper—and influence gene-control pathways associated with tumor biology, oxidative stress, and cellular aging.
The company has narrowed its near-term focus to oncology. The U.S. Food and Drug Administration has cleared TELO's Investigational New Drug application for Telomir-Zn, allowing it to proceed toward a Phase 1/2 clinical trial in advanced or metastatic triple-negative breast cancer. In April 2026, Telomir completed its acquisition of TELI Pharmaceuticals, consolidating worldwide rights to Telomir-1 under a single corporate structure. As a pre-revenue company with no approved products, Telomir's valuation is driven primarily by clinical milestones, financing activity, and investor sentiment rather than fundamentals.
Recent Price Action Over 30 Days and the Quarter
Over the last 30 days, TELO fell from roughly $1.23 to about $1.02, a decline of approximately 17%. The move was not linear. In early October the stock surged on elevated volume, reaching an intraday high near $1.58 before giving back nearly all of those gains and drifting lower through the remainder of the month. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The quarterly picture is similarly down, with shares roughly 17% lower than their late-July level near $1.23. The trailing three months have been unusually volatile, however. The stock touched a 52-week low near $0.89 in mid-July, recovered through August and September, and then spiked again in early October before the latest pullback. This pattern reflects a thinly traded micro-cap that is highly sensitive to news flow and financing developments.
Key Drivers Behind the 30-Day Move
The most significant event of the period was a financing announcement. On October 6, 2026, Telomir disclosed an approximately $5.6 million private investment in public equity (PIPE) financing, issuing about 4.84 million shares of common stock at $1.16 per share—a 5% discount to the applicable 10-day volume-weighted average price. The financing included a $1.0 million investment from entrepreneur John Paul DeJoria, an existing significant shareholder, and carried no warrants or convertible securities.
The initial reaction was positive, sending the stock to an intraday high near $1.58 on unusually heavy volume. That gain proved short-lived, and shares reversed as investors weighed the dilutive effect of the new issuance and the company's commitment to file a registration statement covering the resale of the shares. Dilution concerns are a recurring overhang for pre-revenue biotechs that fund operations through equity sales. A reiterated Sell rating from Weiss Ratings in mid-October and the stock's persistent need for additional capital to advance its clinical program further pressured sentiment through the rest of the month.
Broader Quarterly Influences and Risks
The broader three-month trend has been shaped by Telomir's transition from a preclinical to a clinical-stage company. Key milestones during 2026—including FDA clearance of the IND for Telomir-Zn, the closing of the TELI acquisition securing global rights, and the October PIPE financing—have defined the narrative. These developments de-risk the program on paper but also carry meaningful costs, requiring repeated equity financing that dilutes existing holders.
The quarter's volatility, including the mid-July drop toward the 52-week low and the early-October spike, illustrates how quickly sentiment can shift in a low-liquidity micro-cap. Investors are balancing tangible clinical progress against the realities of a company with no revenue, a going-concern disclosure from its auditors, and a reliance on milestone-based and equity capital to fund a Phase 1/2 trial that has yet to dose its first patient. From what I see, this balance remains delicate.
Looking Ahead at Potential Catalysts
The most important near-term catalyst is clinical execution. Investors will be watching for the initiation and initial enrollment of the Phase 1/2 trial of Telomir-Zn in advanced or metastatic triple-negative breast cancer, along with any early safety, tolerability, or dose-selection data. Milestone-based funding commitments tied to the IND and trial initiation could also provide additional capital if the company hits those targets.
Financing remains a central theme. As a pre-revenue company, Telomir will likely need to raise additional capital, and the structure and pricing of any future offerings will influence the share count and investor sentiment. Broader risk factors include the going-concern disclosure, regulatory and clinical trial risks, competition in oncology drug development, and the inherent volatility of micro-cap biotech stocks. These are watch items for monitoring the company's progress rather than a basis for any specific investment decision. I’m watching this closely as the story unfolds.
Exploring AI-Driven Trading Approaches
In my analysis of volatile names like this one, I find it useful to review systematic strategies alongside fundamental developments. Tickeron’s Trending AI Robots page curates a selection of AI-driven trading bots from a broader universe of hundreds of automated strategies that monitor thousands of tickers. Only top-performing and most relevant bots appear in this featured section, with each bot differing in strategy, timeframe, and performance metrics to suit a range of trading styles. The page is designed to help traders evaluate algorithm-driven approaches across varying market conditions and holding periods. For investors looking to complement their own research with systematic, data-driven tools, the Trending AI Robots section offers a practical starting point.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TELO's RSI Oscillator recovers from oversold territory
The RSI Indicator for TELO moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 15 similar instances when the indicator left oversold territory. In 14 of the 15 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where TELO advanced for three days, in 92 of 118 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
TELO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 25 of 41 cases where TELO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TELO as a result. In 43 of 51 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for TELO turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 28 similar instances when the indicator turned negative. In 26 of the 28 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
TELO moved below its 50-day moving average on October 07, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TELO crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TELO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. TELO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.937) is normal, around the industry mean (2.974). P/E Ratio (-0.919) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.004) settles around the average of (135.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TELO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
Tickeron Innovates Profitable Trading with AI-Based Trend Prediction Engine (TPE)
What constitutes a favorable Debt-to-Income (DTI) Ratio, and what methods are used to determine it?
What are the key advantages of a Backdoor Roth IRA?
What Is a Tax-Free Savings Account?
Asset Acquisition: Top Market Leaders
General Information
Industry Biotechnology
Advertisement